Mission
Critical Path Institute (C-Path) leads collaborations that accelerate drug development, advancing better treatments for people worldwide. Established through a public-private partnership with the U.S. Food and Drug Administration (FDA), C-Path focuses on creating innovative solutions that improve predictability and efficiency in therapeutic development and regulatory processes. Their work fosters collaboration among regulators, biotech companies, and patient advocates to address unmet medical needs and facilitate the development of safer, effective medications.
Basic Information
Tax-Exempt
Founded in
2004
EIN
20-1991334
Total Assets
$26.73 million
UN Sustainable Development Goals Supported
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
Showing 2 of 2 goals
At a Glance
C-Path Overview Video
A short video providing an overview of C-Path's mission and work.
Patient Advocate Stories
Testimonials from patients discussing the impact and importance of C-Path's work.
Annual Report 2023
Detailed insights into C-Path's achievements and roadmap for the future.
Impact Stats
50
Years since last treatment
New Treatment for Tuberculosis
C-Path contributed to process improvements that led to the first new treatment and regimen for tuberculosis in over 50 years.
1
Drug approvals
Imaging Biomarker for PKD
Developed the first imaging biomarker for polycystic kidney disease, which contributed to the approval of the first drug to slow disease progression.
2
Regulatory endorsements
Alzheimer's Disease Clinical Trial Tool
Created the first computerized tool to optimize clinical trial design for Alzheimer's disease, endorsed by FDA and EMA.
Past Events
Scientific Breakthrough Summit
October 26, 2023
The C-Path Scientific Breakthrough Summit showcased the latest advancements in drug development strategies.
Predictive Safety Testing Consortium
June 13, 2023
Discussion about advancements in pancreatic injury biomarkers crucial for drug-induced injury detection.
Rare Disease Moonshot Launch
December 8, 2022
Launch of the Critical Path for Rare Neurodegenerative Diseases initiative focused on developing effective therapies.
Upcoming Events
2024 Clinical Outcome Assessment Program Annual Meeting
August 15, 2024
An annual meeting focused on clinical outcome assessments in drug development.
Learn MoreOur Programs
Rare and Orphan Diseases Program
Facilitates collaboration to speed development in rare diseases.
Learn MoreVolunteer Opportunities
Research Volunteer
Assist in data collection and analysis for ongoing research projects.
Advocacy Volunteer
Help raise awareness and advocate for patient-centered drug development.
Testimonials
"C-Path is helping the industry by developing tools that can help optimize clinical trial designs."
Joe Montminy
Advocate for All People Living with Dementia
"Working with C-Path gives me hope because I’ve seen collaboration advancing therapeutic development."
Phil Green
Patient Advocate
Impact Reports
MIP Score (Beta)
The MIP Score is in beta! We'd love any feedback you may have.
The MIP Score and it's methodology is purely used as a way to visualize how a nonprofits public financial data compares against others. It doesn't reflect the unique circumstances and impact that a nonprofit has.The MIP Score should never be used to say one charity is better than another.
Overall Score
70
50
/100
Program Expense Ratio
81.92%
14
/20
Program Revenue Growth
39.27%
18
/20
Leverage Ratio
0.4288
10
/20
Working Capital Ratio
0.4769
6
/20
Fundraising Efficiency
0
2
/20
Latest Filing Data: Form 990
Fiscal Year:2022
Source:Source: Self-reported by organization
Financial Details
Revenue
| Category | Amount | Percentage |
|---|---|---|
| Contributions, Gifts, and Grants | 23.56M | 66.80% |
| Program Services | 11.29M | 32.02% |
| Investment Income | 403.8K | 1.15% |
| Sales of Non-Inventory Assets | 0 | 0.00% |
| Other Notable Sources | 14K | 0.04% |
| Total Revenue | 35.27M | 100.00% |